|
|
Post by itellthefuture777 on Mar 9, 2021 13:13:57 GMT -5
Clofazimine is used to treat leprosy? So patient totals are in the teens and all on one island. What am I missing? Oh, if inhaled used to treat MAC for nontuberculous mycobacterial Lung disease. Interesting turn for an inhaled med. Covid-19... Clofazimine is a broad-spectrum coronavirus inhibitor that ...www.ncbi.nlm.nih.gov › pmc › articles › PMC7553155 by S Yuan · Cited by 4 — COVID-19 pandemic is the third zoonotic coronavirus (CoV) outbreak of the century after severe acute respiratory syndrome (SARS) in 2003 and Middle East ... Introduction · Results · Discussion · Materials And Methods www.ncbi.nlm.nih.gov/pmc/articles/PMC7553155/in-vitro study on an oral antimicrobial clofazimine for treatment of non-tuberculous mycobacterium infection has been proven to reduce SARS-CoV-2 viral load. clinicaltrials.gov/ct2/show/NCT04465695Furthermore, clofazimine, an FDA-approved molecule on the WHO Model List of Essential Medicines, showed an antiviral EC50 of 310 nM. This molecule has anti-mycobacterial and anti-inflammatory activity39, and is used for the treatment of leprosy. Further studies are required to understand the mechanism by which this drug blocks the replication of SARS-CoV-2. www.nature.com/articles/s41586-020-2577-1Also Clofazimine also has been sporadically reported with some success in other autoimmune diseases such as psoriasis,[26] Miescher's granulomatous cheilitis.[27] Also Type 1 Diabetes A mechanistic studying of clofazimine in human T cells revealed that this drug is a Kv1.3 (KCNA3) channel blocker.[21] This indicates that clofazimine will be potentially used for treatment of multiple sclerosis, rheumatoid arthritis and type 1 diabetes. en.wikipedia.org/wiki/ClofazimineAlso cryptosporidiosis Love, M. S. et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Negl. Trop. Dis. 11, e0005373 (2017). Also for Lung Transplant infections.. Novel Administration of Clofazimine for the Treatment of ...academic.oup.com › ofid › article › ofaa183 by E Valinetz · 2020 — We report the successful administration of clofazimine via gastrostomy tube to a post–lung transplant recipient with disseminated MAC infection. Also Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts pubmed.ncbi.nlm.nih.gov/32310272/ |
|
|
|
Post by wsulylecoug on Mar 9, 2021 13:19:41 GMT -5
|
|
|
|
Post by longliner on Mar 9, 2021 13:44:46 GMT -5
Clofazimine is used to treat leprosy? So patient totals are in the teens and all on one island. What am I missing? Oh, if inhaled used to treat MAC for nontuberculous mycobacterial Lung disease. Interesting turn for an inhaled med. Covid-19... Clofazimine is a broad-spectrum coronavirus inhibitor that ...www.ncbi.nlm.nih.gov › pmc › articles › PMC7553155 by S Yuan · Cited by 4 — COVID-19 pandemic is the third zoonotic coronavirus (CoV) outbreak of the century after severe acute respiratory syndrome (SARS) in 2003 and Middle East ... Introduction · Results · Discussion · Materials And Methods www.ncbi.nlm.nih.gov/pmc/articles/PMC7553155/in-vitro study on an oral antimicrobial clofazimine for treatment of non-tuberculous mycobacterium infection has been proven to reduce SARS-CoV-2 viral load. clinicaltrials.gov/ct2/show/NCT04465695Furthermore, clofazimine, an FDA-approved molecule on the WHO Model List of Essential Medicines, showed an antiviral EC50 of 310 nM. This molecule has anti-mycobacterial and anti-inflammatory activity39, and is used for the treatment of leprosy. Further studies are required to understand the mechanism by which this drug blocks the replication of SARS-CoV-2. www.nature.com/articles/s41586-020-2577-1Also Clofazimine also has been sporadically reported with some success in other autoimmune diseases such as psoriasis,[26] Miescher's granulomatous cheilitis.[27] Also Type 1 Diabetes A mechanistic studying of clofazimine in human T cells revealed that this drug is a Kv1.3 (KCNA3) channel blocker.[21] This indicates that clofazimine will be potentially used for treatment of multiple sclerosis, rheumatoid arthritis and type 1 diabetes. en.wikipedia.org/wiki/ClofazimineAlso cryptosporidiosis Love, M. S. et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Negl. Trop. Dis. 11, e0005373 (2017). Also for Lung Transplant infections..
Novel Administration of Clofazimine for the Treatment of ...academic.oup.com › ofid › article › ofaa183
by E Valinetz · 2020 — We report the successful administration of clofazimine via gastrostomy tube to a post–lung transplant recipient with disseminated MAC infection.Also Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts pubmed.ncbi.nlm.nih.gov/32310272/This is exactly what UTHR is growing...lungs for transplant! |
|
|
|
Post by nylefty on Mar 9, 2021 13:51:12 GMT -5
|
|
|
|
Post by itellthefuture777 on Mar 9, 2021 13:51:18 GMT -5
Covid-19... Clofazimine is a broad-spectrum coronavirus inhibitor that ...www.ncbi.nlm.nih.gov › pmc › articles › PMC7553155 by S Yuan · Cited by 4 — COVID-19 pandemic is the third zoonotic coronavirus (CoV) outbreak of the century after severe acute respiratory syndrome (SARS) in 2003 and Middle East ... Introduction · Results · Discussion · Materials And Methods www.ncbi.nlm.nih.gov/pmc/articles/PMC7553155/in-vitro study on an oral antimicrobial clofazimine for treatment of non-tuberculous mycobacterium infection has been proven to reduce SARS-CoV-2 viral load. clinicaltrials.gov/ct2/show/NCT04465695Furthermore, clofazimine, an FDA-approved molecule on the WHO Model List of Essential Medicines, showed an antiviral EC50 of 310 nM. This molecule has anti-mycobacterial and anti-inflammatory activity39, and is used for the treatment of leprosy. Further studies are required to understand the mechanism by which this drug blocks the replication of SARS-CoV-2. www.nature.com/articles/s41586-020-2577-1Also Clofazimine also has been sporadically reported with some success in other autoimmune diseases such as psoriasis,[26] Miescher's granulomatous cheilitis.[27] Also Type 1 Diabetes A mechanistic studying of clofazimine in human T cells revealed that this drug is a Kv1.3 (KCNA3) channel blocker.[21] This indicates that clofazimine will be potentially used for treatment of multiple sclerosis, rheumatoid arthritis and type 1 diabetes. en.wikipedia.org/wiki/ClofazimineAlso cryptosporidiosis Love, M. S. et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Negl. Trop. Dis. 11, e0005373 (2017). Also for Lung Transplant infections..
Novel Administration of Clofazimine for the Treatment of ...academic.oup.com › ofid › article › ofaa183
by E Valinetz · 2020 — We report the successful administration of clofazimine via gastrostomy tube to a post–lung transplant recipient with disseminated MAC infection.Also Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts pubmed.ncbi.nlm.nih.gov/32310272/This is exactly what UTHR is growing...lungs for transplant! Yes and also Covid-19 and many other indications..this is huge..way huge..and it's like hey people! This is Covid-19 treatment as well as multiple indications! This alone you would think the stock would be over 3 billion..safer application of a Covid-19 treatment..also many other areas related to type 1 diabetes..lungs..others.. |
|
|
|
Post by Clement on Mar 9, 2021 14:19:42 GMT -5
shows mnkd101 (clofazimine) moving to phase 1 in 4th quarter. |
|
|
|
Post by itellthefuture777 on Mar 9, 2021 14:44:48 GMT -5
www.newscientist.com/article/2110555-superfast-therapy-cracks-multidrug-resistant-tuberculosis/A new regime of seven antibiotics has been shown to vanquish multidrug-resistant tuberculosis (MDR-TB) within just nine months, less than half the time it takes with current treatments. One of the antibiotics – clofazimine – was until recently used mainly to treat leprosy. In all, 821 of the 1006 people with MDR-TB treated with the new course of drugs across nine African countries were cured in a two-year study. “That’s 82 per cent, which is excellent, and with treatments lasting just nine months,” says Valérie Schwoebel at the International Union Against Tuberculosis and Lung Disease, which unveiled the results this week at an international conference on lung health in Liverpool, UK. The standard treatment that it could now replace cures only 55 per cent of people, with many dying because they abandon the prolonged treatment of 20 months or more. The new regime is also cheaper: Schwoebel estimates that it costs less than $1000 per person, compared with at least $3000 for the current treatment. Promising results The results replicate those of earlier, smaller studies, providing extra reassurance that the treatment works. Preliminary results from the trial released in December prompted the World Health Organization in May to recommended replacing the old treatment with the new regime. “With strong evidence now showing that this regimen is the most effective available for treating multidrug-resistant forms of TB, the next step is for countries to begin widely implementing this new approach,” said Arnaud Trebucq, who presented the results in Liverpool. “The new regime is nice, because it’s less toxic and much shorter,” says Mario Raviglione, director of the WHO’s global TB programme. But he cautions that it can only be given to around a third to half of all cases worldwide, because it will not work if people are already resistant to certain “second-line” drugs used to treat tuberculosis if standard treatments fail. Provided that people are only resistant to the classic antibiotics rifampacin or isoniazid, the regime can be used. Raviglione says that in most African countries, resistance to second-line drugs remains rare, so the regime can be widely used. However, such resistance is common in the former Soviet Union, so the regime will be less applicable there. Global threat For now, the disease remains a global threat. MDR-TB continues to spread, with many people not receiving any treatment, according to the WHO in its Global Tuberculosis Report published this month. “The crisis of MDR-TB detection and treatment continues,” it warns. Of 580,000 people newly diagnosed with MDR-TB in 2015, only a fifth received the existing therapy, and 250,000 died. Three countries – India, China and Russia – account for almost half of all cases. Schwoebel says the main reason for the continued spread is the failure of people with ordinary TB to complete their six-month treatment regime. The result is that the bacteria survive and develop resistance, then spread to others. “This crisis is created through countries with badly functioning programmes,” says Schwoebel. “So the population with MDR-TB is growing despite the fact we have good tests, good diagnosis and now improved treatments.” Read more: www.newscientist.com/article/2110555-superfast-therapy-cracks-multidrug-resistant-tuberculosis/#ixzz6oe6N3ZLqRead more: www.newscientist.com/article/2110555-superfast-therapy-cracks-multidrug-resistant-tuberculosis/#ixzz6oe6Gyc6P
|
|
|
|
Post by itellthefuture777 on Mar 9, 2021 15:02:35 GMT -5
wwwnc.cdc.gov/eid/article/27/3/20-4418_articleIn the World Health Organization European Region, the proportion of rifampin-resistant and MDR TB is greater than the global average. New drug regimens incorporating bedaquiline, clofazimine, linezolid, and delamanid to treat MDR and XDR TB have been recommended by the World Health Organization and are being implemented globally
|
|
|
|
Post by itellthefuture777 on Mar 9, 2021 15:05:20 GMT -5
|
|
|
|
Post by itellthefuture777 on Mar 9, 2021 15:08:43 GMT -5
|
|
|
|
Post by itellthefuture777 on Mar 9, 2021 15:11:02 GMT -5
www.telegraphindia.com/health/tuberculosis-drug-shortage-alert/cid/1748324clofazimine NPPA officials considered the request and observed that Abbott has 'near monopoly' with around 98 per cent of the market share of these 'critical medicines' for TB and leprosy and 'a sudden discontinuation' could lead to shortages. My assessment: Abbott is monopoly of clofazimine and if MNKD makes a version that is more potent and uses less drug then it solves Abbotts issue. Also odd it is in short supply if this is a Covid-19 solution we'll be paying India a lot of money to get it so MNKD reduces that cost imo.
|
|
|
|
Post by itellthefuture777 on Mar 9, 2021 15:53:58 GMT -5
www.telegraphindia.com/health/tuberculosis-drug-shortage-alert/cid/1748324clofazimine NPPA officials considered the request and observed that Abbott has 'near monopoly' with around 98 per cent of the market share of these 'critical medicines' for TB and leprosy and 'a sudden discontinuation' could lead to shortages. My assessment: Abbott is monopoly of clofazimine and if MNKD makes a version that is more potent and uses less drug then it solves Abbotts issue. Also odd it is in short supply if this is a Covid-19 solution we'll be paying India a lot of money to get it so MNKD reduces that cost imo. That said Abbott imo is a potential partner for clofazimine..mark it |
|
|
|
Post by neil36 on Mar 9, 2021 16:36:27 GMT -5
So who would be the most likely distributor/partner for Afrezza distribution in the European Union?
|
|
|
|
Post by itellthefuture777 on Mar 9, 2021 16:47:43 GMT -5
So who would be the most likely distributor/partner for Afrezza distribution in the European Union? Abbott is global so maybe they partner and distribute co-promote Afrezza in EU. Hmm then again I noticed top executives at Sanofi and Bayer switching places..and a partnering between Bayer and Sanofi. Also between Abbott and Sanofi..Hmm Seems Sanofi has it's fingers in all the pies in town..Sanofi seems to guard MNKD like a dog his food bowl..having these levers isn't helpful if Sanofi isn't going to do the right thing. Hmm..well..if it is Sanofi..it makes sense as well..but it's going to cost them $10 billion upfront and they give mnkd 77% until sales reach a certain limit..imo a reverse milestone deal |
|
|
|
Post by wmdhunt on Mar 9, 2021 17:12:12 GMT -5
If only this revenge on Sanofi could happen! They certainly deserve a swift kick for what they did way back when.
|
|
